Address
L7 General Purpose South Building
Staff House Rd
The University of Queensland
QLD, 4072, Australia
Contact
Marsewi Ngatimin+610427945116
m.ngatimin@uniquest.com.au
Website
Antibiotics for MDR/XDR Gram-Negative Infections
A novel class of octapeptin derivatives with improved activity against multiple gram-negative bacteria strains.
Novel lipopeptide antibiotics that targets the most critical pathogens identified by WHO; Greater efficacy with significantly reduced nephrotoxicity
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial compound/strategy
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Academia
- Company
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Oceania
- North America
- South America
- Eurasia
- Africa
N.A.
UniQuest Pty Limited is The University of Queensland’s commercialisation company
Potential for these novel lipopeptides as a “resistance breaker” to synergise with existing antibiotics to potentiate their activity against MDR/XDR bacteria
